The association between ATRX and ABCG2 levels in brain tumors, particularly in gliomas, highlights the complex interplay of genetic alterations and drug resistance mechanisms that influence tumor behavior and therapeutic outcomes. This evidence concerns the gene ABCG2 and glioma.